Clinical Trials in Suzhou, Jiangsu
3 recruiting
Showing 1–20 of 27 trials
Recruiting
Phase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC600 enrolled212 locationsNCT06345729
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC520 enrolled156 locationsNCT06305754
Recruiting
Phase 3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Merck Sharp & Dohme LLC780 enrolled257 locationsNCT06312137
Recruiting
Phase 3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Mirati Therapeutics Inc.630 enrolled337 locationsNCT06875310
Recruiting
Phase 3
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Pfizer900 enrolled240 locationsNCT06629779
Recruiting
Phase 3
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Prostate CancerCancer of the ProstateHormone Sensitive Prostate Cancer+1 more
Pfizer1,000 enrolled188 locationsNCT07028853
Recruiting
Phase 3
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Pfizer600 enrolled235 locationsNCT06551324
Recruiting
Phase 3
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
OncoC4, Inc.630 enrolled152 locationsNCT05671510
Recruiting
Phase 3
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
HER2-positive Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.416 enrolled69 locationsNCT07047365
Recruiting
Phase 1Phase 2
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
Advanced Solid Tumor
Jacobio Pharmaceuticals Co., Ltd.334 enrolled32 locationsNCT06959615
Recruiting
Phase 2
A Study of YL202 in Selected Patients With Advanced Solid Tumors
Breast CancerNSCLCHNSCC+1 more
MediLink Therapeutics (Suzhou) Co., Ltd.200 enrolled82 locationsNCT06107686
Recruiting
Phase 3
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
Nuvation Bio Inc.138 enrolled29 locationsNCT06564324
Recruiting
Phase 3
Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Breast Cancer
Laekna Limited256 enrolled55 locationsNCT04851613
Recruiting
Phase 1Phase 2
TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer
RAS/BRAF Wild Type Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.72 enrolled27 locationsNCT07044908
Recruiting
Not Applicable
The Application of "HUAXI Hole 1" in Reverse-sequence Endoscopic Nipple-sparing Mastectomy With Direct-to-implant Breast Reconstruction
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Du Zhenggui337 enrolled20 locationsNCT06995118
Recruiting
Multi-omics Detection Techniques for Differentiating Benign and Malignant Pulmonary Nodules
Lung Cancer (Diagnosis)Pulmonary Nodule Persistent
Zhao Jun150 enrolled1 locationNCT07047573
Recruiting
Phase 1Phase 2
Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
Prostate Cancer
Bivision Pharmaceuticals, Inc.90 enrolled13 locationsNCT06139575
Recruiting
Phase 3
To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Allist Pharmaceuticals, Inc.318 enrolled1 locationNCT04853342
Recruiting
Phase 3
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
Triple Negative Breast Cancer(TNBC)
Biotheus Inc.360 enrolled70 locationsNCT06419621
Recruiting
Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients
Esophageal CancerLung Cancer
Zhao Jun50 enrolled1 locationNCT06790797